We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Stratophase Collaborates with LGC on Real-Time Monitoring of 3D Cell Culture Growth
News

Stratophase Collaborates with LGC on Real-Time Monitoring of 3D Cell Culture Growth

Stratophase Collaborates with LGC on Real-Time Monitoring of 3D Cell Culture Growth
News

Stratophase Collaborates with LGC on Real-Time Monitoring of 3D Cell Culture Growth

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Stratophase Collaborates with LGC on Real-Time Monitoring of 3D Cell Culture Growth"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Stratophase has announced that it is collaborating with LGC, the UK’s designated National Measurement Institute for chemical and bioanalytical measurement, to validate Stratophase’s novel technology, which has the potential to improve cell bioprocessing methods.

Cell-based measurements underpin research and development pipelines of key UK industries, including pharmaceutical, cosmetics and healthcare. Improving the cell manufacturing scale-up process offers potential benefits to the biopharma and regenerative medicine sectors by reducing costs of cell-based products, and improving the speed to clinic.

Current monitoring of the growth of the cells in a bioreactor system usually requires sub-sampling to measure cell number, a procedure which increases the risk of bio-contamination. Therefore the ability to monitor cell growth continually, and subsequently optimize conditions for increased yield and purity is vital. LGC has extensive experience in the scale-up of mammalian cells for biomarker expression, genetic stability testing and cell therapy and is employing a novel imaging system to measure cell growth accurately on a three dimensional (3D), free floating scaffold in a bioreactor system.

By using Stratophase’s SpectroSens insertion probe, LGC has demonstrated its potential to improve the monitoring of cell growth in a 3D culture by enabling real-time measurement of nutrient metabolism and the build-up of waste products. SpectroSens complements standard bioreactor probe technologies for measuring pH and oxygen levels, offering a tool for real-time monitoring of changes within the bioreactor system, and enabling better control over the bioreactor environment to promote optimal cell growth.

Damian Marshall, LGC’s Principal Scientist for cell biology, commented, “We are pleased to be involved in demonstrating how the SpectroSens monitoring technology can help maximize cell growth rates while minimizing undue cellular stress, opening a route to rapid process development and scale-up, key to enabling cell therapies to become a mainstream medical treatment.”

Richard Williams, Stratophase’s chief executive said, “Our SpectroSens technology has already proven itself in the real-time monitoring of a number of processes such as fermentations and continuous flow reactions. We are delighted to build on this success by working with LGC to demonstrate its ability to improve the monitoring of 3D cell culture, with the ultimate aim of fast-tracking the development of cell therapies”.
Advertisement